Skip to main content
. 2020 Oct 15;12(10):2991. doi: 10.3390/cancers12102991

Figure 2.

Figure 2

Impact of C2- and C1-ligands on the frequency of KIR2DL1+ and KIR2DL2/S2+ CD8+ T cell subsets and on patient survival. (A) Frequency of KIR2DL1+ CD8+ T cells (% of total lymphocytes) in all patients (n = 249), patients who survived (Living, n = 208), and patients who died during the follow-up (Dead, n = 41) according to the presence of the specific C2-ligand. ** p < 0.01. (B) Frequency of KIR2DL1+ CD8+ T cells in healthy controls and in living melanoma, bladder, and ovarian cancer patients. (C) Frequency of KIR2DL2/S2+ CD8+ T cells in all, living, and dead patients according to the presence of their specific C1-ligand. (D) Frequency of KIR2DL2/S2+ CD8+ T cells in dead melanoma, bladder, and ovarian cancer patients. (E) Frequency of KIR2DL2/S2+ CD8+ T cells in living and dead cancer patients according to the dose of its specific C1-ligands. (F) Kaplan-Meier and Log-rank tests for overall survival (OS) of solid cancer patients (n = 248) according to the presence of C1- and C2-ligands.